Are you a candidate for SUPARTZ® Joint Fluid Therapy?

You could be if:

• Your knee pain is due to osteoarthritis
• You are not getting adequate OA knee pain relief from walking and/or physical therapy
• You are not getting adequate OA knee pain relief from pain medications, including:
  • Ibuprofen (e.g. Advil®)
  • Acetaminophen (e.g. Tylenol®)
  • Naproxen sodium (e.g. Aleve®)
  • Cox-2s/NSAIDs: (Celebrex®, Bextra®, MOBIC®)

If you meet the three criteria above, ask your doctor if SUPARTZ Joint Fluid Therapy is right for you!

You should not have SUPARTZ Joint Fluid Therapy if:

• You are allergic to products from birds such as feathers, eggs and poultry.
• You have infections or skin diseases in the area the injection will be given.
• You have had any previous allergic reactions to SUPARTZ Joint Fluid Therapy or similar material, i.e., hyaluronate products.

The safety and effectiveness of SUPARTZ Joint Fluid Therapy have not been established in pregnant women, in lactating women and in children.

The following were the most common adverse events occurring in SUPARTZ Joint Fluid Therapy-treated patients:

• Joint pain with no evidence of inflammation
• Joint pain with evidence of inflammation
• Back pain, pain (non-specific)
• Injection site reaction
• Headache
• Injection-site pain.

These adverse events also occurred at similar rates in the patients treated with a saltwater placebo.

Download the Package Insert

After Your Treatment

For 48 hours after receiving an injection, you should avoid activities such as jogging, tennis, heavy lifting, or long periods of standing. Keep in mind that no treatment — including SUPARTZ Joint Fluid Therapy — helps every single patient.

Product History

SUPARTZ Joint Fluid Therapy was the first hyaluronan joint fluid therapy available for human use in treating the pain of osteoarthritis. It was introduced in Japan in 1987 and approved for use in the US in 2001. Since 1987, more than 155 million injections have been sold.

SUPARTZ Joint Fluid Therapy has proven its effectiveness. It has a long and broad clinical history, including follow-up studies lasting six years. In these studies, SUPARTZ joint fluid therapy groups showed no more frequency of adverse event incidence than the placebo control group.